22:43 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest CSF1R inhibitors could help treat age-related neurodegeneration. In a mouse model of age-related neurodegeneration, a tool compound CSF1R inhibitor decreased markers of age-related neuropathy including the numbers of thinly myelinated...
20:19 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Cabiralizumab in Phase II for pancreatic cancer, Five Prime receives $25M milestone

Bristol-Myers Squibb Co. (NYSE:BMY) began a Phase II trial to evaluate cabiralizumab (FPA008) plus Opdivo nivolumab with and without chemotherapy in patients with locally advanced or metastatic pancreatic cancer that progressed during or after one...
23:25 , Jan 9, 2018 |  BioCentury  |  Finance

Stars in China

A major clinical flop and a spate of weak earnings reports by U.S. large cap biotechs reverberated throughout the sector in the fourth quarter, breaking a three-quarter-long streak of outperformance. Across all market cap bands,...
04:59 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

Five Prime reports Phase I data for cabiralizumab in pancreatic cancer

Five Prime Therapeutics Inc. (NASDAQ:FPRX) reported preliminary data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announced upcoming trials sponsored by partner...
23:25 , Nov 8, 2017 |  BC Extra  |  Clinical News

Five Prime regains ground on cabiralizumab update

Five Prime Therapeutics Inc. (NASDAQ:FPRX) added $4.58 (18%) to $30.44 on Wednesday after reporting updated data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid...
00:38 , Nov 8, 2017 |  BC Extra  |  Clinical News

Five Prime down on disappointing cabiralizumab combo data

Five Prime Therapeutics Inc. (NASDAQ:FPRX) plummeted $17.90 (41%) to $25.86 on Tuesday following a preliminary Phase Ia data readout for cabiralizumab (FPA008) in combination with Opdivo nivolumab to treat advanced solid tumors. The data were...
16:30 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Cabiralizumab: Completed Ph I/II enrollment

Five Prime completed enrollment of 30 patients in the Phase II portion of an open-label, international Phase I/II trial evaluating IV cabiralizumab every 2 weeks. The trial enrolled 45 patients in total. The company plans...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Five Prime, Bristol-Myers deal

Five Prime granted Bristol-Myers Squibb exclusive, worldwide rights to its colony-stimulating factor 1 receptor ( CSF1R; C-FMS; CD115) antibody program, including clinical candidate FPA008. The deal replaces a 2014 agreement to test...
02:24 , Oct 16, 2015 |  BC Extra  |  Top Story

BMS licenses Five Prime's CSF1R program

Five Prime Therapeutics Inc. (NASDAQ:FPRX) jumped $11.02 (65%) to $27.93 on Thursday after it granted Bristol-Myers Squibb Co. (NYSE:BMY) an exclusive, worldwide license to its colony stimulating factor 1 receptor ( CSF1R; CD115) antibody program,...